Bausch Health Companies Inc.'s (NYSE:BHC) Path To Profitability
Bausch Health Companies Inc.'s (NYSE:BHC) Path To Profitability
Bausch Health Companies Inc. (NYSE:BHC) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. The US$3.5b market-cap company posted a loss in its most recent financial year of US$592m and a latest trailing-twelve-month loss of US$178m shrinking the gap between loss and breakeven. The most pressing concern for investors is Bausch Health Companies' path to profitability – when will it breakeven? Below we will provide a high-level summary of the industry analysts' expectations for the company.
bausch health公司可能即将取得业务上的重大成就,因此我们希望介绍一下这家公司。bausch health公司在美国和国际上作为一家多元化的专业药品和器械公司运营。这家市值35亿美元的公司在最近一财年亏损了59200万美元,并在最新的滚动十二个月亏损了17800万美元,缩小了亏损与盈亏平衡之间的差距。投资者最关注的问题是bausch health公司实现盈利的路径——何时能够盈亏平衡?接下来我们将对公司行业分析师对该公司的预期进行高层次的总结。
Bausch Health Companies is bordering on breakeven, according to the 7 American Pharmaceuticals analysts. They expect the company to post a final loss in 2024, before turning a profit of US$405m in 2025. The company is therefore projected to breakeven just over a year from now. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 218%, which is extremely buoyant. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.
根据7位美国药品分析师的说法,bausch health公司快要实现盈亏平衡了。他们预计该公司在2024年再次亏损,然后在2025年实现40500万美元的利润。因此,预计该公司将在一年多的时间内实现盈亏平衡。为了在这个日期实现盈亏平衡,该公司每年需要以什么样的增长率发展呢?使用最佳拟合线,我们计算出年均增长率为218%,这是非常乐观的。如果该增长率过于激进,公司可能比分析师预测的盈利时间晚得多。
We're not going to go through company-specific developments for Bausch Health Companies given that this is a high-level summary, though, keep in mind that typically pharmaceuticals, depending on the stage of product development, have irregular periods of cash flow. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.
考虑到这是一个高层次的总结,我们不会详细介绍bausch health公司的具体发展情况,不过,请记住,通常情况下,根据产品开发阶段的不同,药品公司的现金流水平会有不规律的周期。因此,高增长率并不罕见,尤其是当一家公司处于投资时期时。
Before we wrap up, there's one issue worth mentioning. Bausch Health Companies currently has negative equity on its balance sheet. Accounting methods used to deal with losses accumulated over time can cause this to occur. This is because liabilities are carried forward into the future until it cancels. These losses tend to occur only on paper, however, in other cases it can be forewarning.
在完成之前,有一个值得一提的问题。bausch health公司目前的资产负债表上有负净值。处理长期积累的损失的会计方法可能导致这种情况发生。这是因为负债会一直延续到未来,直到清零。这些损失往往只在纸面上出现,然而,在其他情况下,它可能是一个不祥之兆。
Next Steps:
下一步:
There are too many aspects of Bausch Health Companies to cover in one brief article, but the key fundamentals for the company can all be found in one place – Bausch Health Companies' company page on Simply Wall St. We've also compiled a list of key factors you should further examine:
Bausch Health公司有太多方面需要在一篇简短的文章中涵盖,但是公司的关键基本面都可以在一个地方找到 - Bausch Health公司的Simply Wall St公司页面。我们还编制了一个关键因素清单,您应该进一步检查:
- Valuation: What is Bausch Health Companies worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Bausch Health Companies is currently mispriced by the market.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Bausch Health Companies's board and the CEO's background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
- 估值:波讯健康公司今天的价值是多少?未来的增长潜力是否已经被市场计入了价格中?我们免费的研究报告中的内在价值信息图可以帮助你直观地了解波讯健康公司是否当前被市场定价错误。
- 管理团队:一支经验丰富的管理团队可以增加我们对业务的信心——请看看谁坐在Bausch Health Companies的董事会和CEO的背景。
- 其他高表现的股票:是否有其他表现更好的股票并具有经过验证的历史记录?查看这里的免费列表。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧吗?请直接与我们联系。或者,发送电子邮件至editorial-team @ simplywallst.com。
Simply Wall St的这篇文章是一般性质的。我们仅基于历史数据和分析师预测提供评论,使用公正的方法,我们的文章并非意在提供财务建议。这并不构成买入或卖出任何股票的建议,并且不考虑您的目标或财务状况。我们旨在为您带来基于基础数据驱动的长期聚焦分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St对提及的任何股票都没有持仓。